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Abstract: A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern,
and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet,
its poor water solubility, stability, and bioavailability hinder clinical application. In this study, we
have explored a nanosized carbon nanoparticle—C60 fullerene (C60)—for optimized Ber delivery
into leukemic cells. Water dispersions of noncovalent C60-Ber nanocomplexes in the 1:2, 1:1, and
2:1 molar ratios were prepared. UV–Vis spectroscopy, dynamic light scattering (DLS), and atomic
force microscopy (AFM) evidenced a complexation of the Ber cation with the negatively charged
C60 molecule. The computer simulation showed that -stacking dominates in Ber and C60 binding
in an aqueous solution. Complexation with C60 was found to promote Ber intracellular uptake.
By increasing C60 concentration, the C60-Ber nanocomplexes exhibited higher antiproliferative
potential towards CCRF-CEM cells, in accordance with the following order: free Ber < 1:2 < 1:1 < 2:1
(the most toxic). The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM
cells treated with C60-Ber nanocomplexes evidenced apoptosis induction. Thus, this study indicates
that the fast and easy noncovalent complexation of alkaloid Ber with C60 improved its in vitro
eciency against cancer cells.
Keywords: C60 fullerene; Berberine; noncovalent nanocomplex; UV–Vis; DLS and AFM
measurements; drug release; leukemic cells; uptake; cytotoxicity; apoptosis
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1. Introduction
Historically natural products have always provided drugs against a wide variety of diseases,
with cancer being no exception [1]. Herbal secondary metabolites exhibit multiple biological and
pharmacological properties, representing a natural library of bioactive compounds with potentially
high safety, availability, accessibility, and low costs. Alkaloids, being one of the most versatile class of
herbal secondary metabolites, are heterocyclic, nitrogen-containing, low-molecular-weight molecules
that provide plants with a defense against herbivores, bacteria, fungi, and viruses [2–4]. Representatives
of this class often exhibit pharmacological eects and are used as anticancer therapeutics such as
Vinblastine, Vincristine, Paclitaxel, and Camptothecin [5].
The isoquinoline quaternary alkaloid Berberine (Ber: 2,3-methylenedioxy-9,10-
dimethoxyprotoberberine chloride, CAS No. 2086-83-1) is a common drug in Ayurvedic,
Chinese, Middle-Eastern, and native American folk medicines [6,7] due to its broad spectra of biological
activities. Ber applications as a low-cost therapeutic with anti-inflammatory, antimutagenic [8],
antidiabetic [9], antimicrobial, and antiviral eects seem to be promising [4,10]. In recent years, Ber has
been reported to inhibit the proliferation of many cancer cell lines originated from head and neck
squamous carcinoma [11], melanoma [12], leukemia [3,13,14], oral [15], pancreatic [16], colon [17],
breast [18], and prostate cancer [19]. Given the nitrogen atom positive charge [20], Ber interacts
directly with genomic [21,22] and telomeric [23,24] DNA, inducing double-strand breaks, and telomere
stabilization, respectively. The other potential intracellular targets of Ber are DNA topoisomerase I,
POT1 [3], Wnt [17,25], p53 [18,26], NF-kB [27], cyclooxygenase-2, Mcl-1 [15], nucleophosmin/B23 [13],
and death-domain-associated protein [28]. Ber’s anticancer cytotoxicity is associated mainly with
oxidative stress escalation and mitochondrial dysfunction [7,16,19], apoptosis activation, and cell cycle
arrest [10,14,15,18,28].
The antiproliferative properties raise a possibility for its use as an anticancer therapeutic agent;
however, the poor water solubility, stability, and bioavailability [29] limit its clinical applications.
Furthermore, Ber’s hormetic eect [30], when low doses strongly stimulate the growth of cancer cells,
and high doses have an anticancer eect, challenges the suitable dosage range. Delivery nanosystems
could provide a means of overcoming limitations and improving Ber’s anticancer ecacy. The advent of
nanomedicine and application of biocompatible, bioavailable, and nontoxic nanoparticles has brought
significant advances in the field of cancer therapy, oering a customizable and safer treatment option.
C60 fullerene (C60, CAS No. 99685-96-8) [31], a third allotropic form of carbon, has a stable
spherical-like hollow structure with a 0.72 nm diameter, the surface of which consists of 60 carbon
atoms. C60 is a highly ecient “free radical sponge” [32] due to pronounced electrophilicity (the ability
to accept up to six electrons). Wang et al. [33] reported that C60 and its derivatives eciently prevent
peroxidation and membrane breakdown triggered by free radical species and are more eective in
inhibiting lipid peroxidation than a natural antioxidant vitamin E. C60 is a hydrophobic molecule able
to penetrate into both the lipid bilayer and the cell membranes [34,35]. Pristine C60 [36,37] and its
water-soluble derivative [38] were found to be accumulated in mitochondria.
The pristine C60 has a very low solubility in water. However, it can form a stable aqueous colloid
solution (C60FAS), which contains both individual C60 molecules and its nanoaggregates [39,40]. C60 is
active only in a soluble form when its carbon double bounds are freely accessible [41]. Recently we have
demonstrated that C60FAS prevented the restraint stress-induced oxidative disorders in rats’ brain and
heart tissues [42] as well as CCl4-induced acute liver injury [43], more eectively diminished the muscle
fatigue in rats comparable to the known exogenous antioxidants N-acetylcysteine or -alanine [44],
markedly decreased the oxidative stress and enhanced the activity of antioxidant enzymes in rats
with diet-induced obesity [45], had anti-inflammatory and hepatoprotective eects in a model of
acute colonic inflammation [46], and protected the heart and liver of tumor-bearing mice against
Doxorubicin-induced oxidative stress [47].
It is important to note that pristine C60 is not toxic against normal cells at low concentrations:
according to our previous data [48,49], C60FAS at concentrations up to 14.4 as well as 24 g/mL did
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not manifest any toxic eects in rat erythrocytes and thymocytes as well as in human mesenchymal
stem cells, respectively. The estimation of C60FAS impact on Drosophila melanogaster at DNA, tissue,
and organism levels showed that C60 at the concentration 40g/mL does not aect the reproductive
system and embryogenesis [50]. Recently, a low toxicity of C60FAS towards human embryonic kidney
(HEK293) cells and mice (IC50 383.4g/mL, LD50 721 mg/kg) [51] and the selective strong toxic eect
of C60FAS against tumor cells (rat and human glioma cells) and transformed human phagocytes [52]
were demonstrated.
It is known that anticancer drugs used in clinical practice (including gold standards Doxorubicin
and Cisplatin) have long been characterized by a high adverse toxicity. Reducing the side eects of
these drugs can be achieved by creating an eective targeted delivery nanosystem based, for example,
on biocompatible and bioavailable C60 [53]. It was previously shown that, when Doxorubicin or
Cisplatin were immobilized on C60 fullerene, their intracellular concentration in cancer cells was
increased, leading to a pronounced antitumor eect in in vitro and in vivo systems [34,54–60]. Thus,
one can suggest that C60 complexation with a traditional drug is a promising nanoformulation for
targeted drug delivery, substantially increasing its medico-biological eectiveness with a novel dosage
form in the subsequent preclinical screening [61,62].
The purpose of this study (Figure 1) was to test the formation of the C60-Ber nanocomplex in an
aqueous solution using computer simulation and physico-chemical characterization. The nanocomplex
was designed in three molar ratios of C60 to Ber—1:2, 1:1, and 2:1—to investigate whether C60’s
concentration aected complexation ecacy and Ber bioactivity. Finally, the nanocomplex was
applied towards cancer cells in vitro to study whether complexation with C60 aects Ber’s intracellular
accumulation and cytotoxic potential.
Figure 1. The workflow for the development of C60-based cancer chemotherapy with the use of
Berberine (Ber): (1) computer modeling of the C60-Ber nanocomplex; (2) the fast and cost-eective
preparation of nanocomplexes in dierent molar ratios in aqueous solutions; (3) the analytical assessment
of nanocomplex stability to prove its biological applicability; (4) noncovalent complexation of aromatic
Ber molecule with C60, improving its eciency against human leukemic cells.
Leukemic cell lines are common models of human cancer for experimental investigations at the
cellular level. Leukemia, cancer of the body’s blood-forming tissues, including bone marrow and the
lymphatic system, reached 437,033 in terms of new diagnosed cases in 2018, which is an average of 14
out of 100,000 persons per year. Thus, the human leukemic CCRF-CEM cells were chosen as a main
in vitro cancer model for the current research.
2. Materials and Methods
2.1. Chemicals
Roswell Park Memorial Institute medium (RPMI 1640), phosphate buered saline (PBS),
fetal bovine serum (FBS), penicillin/streptomycin, l-glutamin, and Trypsin were obtained from
Biochrom (Berlin, Germany). 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyl tetrazolium bromide (MTT),
ethanol, triton X-100, RNAse A, propidium iodide, and Ber were obtained from Sigma-Aldrich Co.
(St-Louis, MO, USA). Dimethylsulfoxide (DMSO) and trypan blue from Carl Roth GmbH + Co. KG
(Karlsruhe, Germany) were used.
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2.2. Preparation of C60 with a Ber Aqueous Solution
The highly stable purified C60FAS (>99.5%, concentration 2.6 mg/mL) was prepared by
ultrasonication of toluene dissolved C60 in aqueous phase [40].
Cationic Ber [C20H18NO4]+ was dissolved in distilled water with an initial concentration of
1 mg/mL.
C60FAS and Ber were mixed in various molar ratios, namely, C60-Ber as 1:1 (208:208 M), 1:2
(208:416 M), and 2:1 (208:104 M). The resulting C60+Ber dispersions were treated in the ultrasonic
disperser for 20 min and afterwards stirred magnetically for 18 h at room temperature.
The working concentrations of the C60-Ber nanocomplexes used for cell treatment are presented
in the following Ber equivalent concentrations in order to compare the eect of nanocomplexes with
the eect of the free alkaloid at the same concentration.
2.3. UV–Vis Spectroscopy
UV–Vis absorption spectra of freshly prepared C60-Ber dispersions were recorded using
a double-beam spectrophotometer SQ-4802 (Unico, Waltham, MA, USA) at room temperature.
The measurements were performed using quartz cells with an optical path length of 1 cm in the range
of 200–500 nm. Initially, we put a mixture of C60FAS (the concentration in the mixture was 0.016 mM)
and Ber (the concentration in the mixture was 0.02 mM) into a cell. In order to maintain the Ber
concentration, constant titration was accomplished using a Ber solution of the same concentration
by sequential dilution of the initial mixture down to zero C60 concentration. Since C60FAS has a
pronounced spectrum in the UV-region, overlapping with the Ber spectrum and containing scattering
in the whole spectral region, it was necessary to exclude it by applying dierential measurements [57];
i.e., C60FAS at a concentration of 0.016 mM was placed in a reference cell and diluted simultaneously
with the dilution of the mixture.
2.4. AFMMeasurement
The atomic force microscopy (AFM) was performed to determine the intermolecular interactions
and the degree of components’ aggregation in layers of the free components (Ber and C60) and their
nanocomplex (C60-Ber). AFM measurements were done with the “Solver Pro M” system (NT-MDT,
Moscow, Russia). A drop of investigated solution was transferred on the atomically smooth substrate
to deposit layers. Measurements were carried out after complete evaporation of the solvent. A freshly
broken surface of mica (SPI supplies, V-1 grade) was used as a substrate. Measurements were carried out
in a semicontact (tapping) mode with AFM probes of the RTPESPA150 (Bruker, 6 N/m, 150 kHz) type.
2.5. DLS Measurement
The intensity size distribution and the values of the polydispersity index (PDI) and the zeta
potential for various freshly prepared aqueous systems containing dierent particles were determined
by dynamic light scattering (DLS) on a Zetasizer Nano-ZS90 (Malvern, Worcestershire, UK) at room
temperature. The instrument was equipped with a He-Ne laser (5 mW) operating at a wavelength of
633 nm. The autocorrelation function of the scattered light intensity was analyzed by the Malvern
Zetasizer software with Smoluchowski approximation. The size distribution was used to calculate the
mean hydrodynamic diameter.
2.6. Ber Release with HPLC-ESI-MS/MS
C60-Ber nanocomplexes were incubated in RPMI over 72 h under the identical conditions adopted
from cell-based experiments (2 mL, 37 C). For sample purification from a released free drug, 500 L
of each sample was filtered with the centrifugal filter devices Amicon Ultra-0.5 3 K (Sigma-Aldrich
Co., St-Louis, MO, USA) according to the manufacturer’s instructions: 14,000 g, 15 min for filtration;
1000 g, 2 min for recovery (reverse spin upside down in a new centrifuge tube).
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The content of the filter device was subjected to the chromate-mass spectrometry. Elution and
separation of Ber was performed using the Eclipse XDB-C18 column under gradient conditions with a
mobile phase of methanol and a 0.1% formic acid water solution. The following linear gradient elution
was used: 5% B held for 0.5 min, then increased to 100% from 0.5 to 3.5 min, then held at 100% B from
3.5 to 4 min, then decreased to 5% B from 4 to 4.5 min, and further held at 5% B for 5 min. The flow
rate was set at 0.7 mL/min. The chromatographic reverse phase conditions and optimized MS/MS
parameters are presented in Table 1. For identification and quantification, the molecular ion of Ber was
chosen (Figure 2a).
Table 1. HPLC-ESI-MS/MS conditions for analysis of Ber.
Chromatographic Conditions
Column, its temperature Agilent Eclipse XDB-C18, 40 C
Mobile phase Acetonitrile:0.1% formic acid in H2O
Flow rate 0.7 mL/min
Run time 5 min
Injection volume 1 L
MS/MS Conditions
Desolvation line temperature 250 C
Heat block temperature 400 C
Target molecular ion 336.25 [M] + m/z
Product ions 321.20, 320.20, 292.25 m/z
Time window 0–5 min
Dwell time 0.2 s
Interface voltage 4.5 kV
Nebulizing gas flow 3 L/min
Drying gas flow 15 L/min
Figure 2. Data of the developed HPLC-ESI-MS method for Ber detection and quantification:
representative MRM-chromatogram of Ber (a) and a calibration curve with the method’s performance
characteristics used for drug content quantification: LOD—limit of detection, S/N—signal/noise ratio,
LOQ—limit of quantitation, RSD—relative standard deviation (b).
HPLC-ESI-MS/MS analysis was performed in positive mode with usage of multiple reactions
monitoring (MRM) mode, which provides the best sensitivity and accuracy of measurements.
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After MS/MS optimization, a unique MRM-transition that includes a precursor and two characteristic
product ions was acquired and used for further identification and quantification. The ionized Ber
molecule ([M]+, 336.25 m/z) was used as a precursor ion with the most abundant fragment ions of
321.20, 320.20, and 292.25 m/z.
Ber calibration standards from 0.03 to 15 g/mL were prepared from a 30 g/mL water stock
solution. These standards were stored in the dark at 40 C. Quantification was achieved using the
regression curve (Figure 2b) according to the linear regression Equation (1):
y = (5,37328e + 006)x + 389633. (1)
The obtained data were normalized with the RPMI control and expressed as a percentage of the
respective control sample, analyzed at 0 h.
2.7. Computer Simulation
The computation of spatial structures as well as the computation of component binding energies
related to particular physical factors were accomplished using an approach similar to that employed
previously in the analysis of C60 complexation with various small molecules [57,61].
Structures of the C60 and Ber molecule were taken from the Protein Data Bank 32 [63] (PDB codes
Ids C60 and Ber, respectively). The structure of the C60-Ber nanocomplex was calculated by the methods
of molecular mechanics using X-PLOR, version 3.1 [64]. The atomic charges were calculated using
Gaussian 03W [65]. The topology and parametrization of their valent interactions were obtained with
the help of XPLO2D software [66].
The intramolecular van der Waals energy of the C60-Ber complexation was calculated using X-PLOR.
The calculation of electrostatic energy was performed by solution of the nonlinear Poisson-Boltzmann
equation (the NLPB method) using DelPhi [67]. The computation of hydrophobic energy was performed
based on a linear correlation between the hydrophobic dissolution energy and a variation of the solvent
accessible surface areas (DSASA) as DGhyd = DSASA, where  = 50 cal/(molÅ2) is a microscopic
surface tension coecient. SASA was calculated using GETAREA, version 1.1 [68].
2.8. Cell Culture
The human cancer T-cell line CCRF-CEM (ACC 240) of leucosis origin was purchased from the
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung
von Mikroorganismen und Zellkulturen, Braunschweig, Germany). CCRF-CEM cells were maintained
in an RPMI 1640 medium, supplemented with 10% FBS, 1% penicillin/streptomycin, and 2 mM
glutamine. Cells were cultured in 25 cm2 culture flasks at a 37 C with 5% CO2 in a humidified
incubator binder (Tuttlingen, Germany). The passaging was performed once cells reached 80%.
Treatment with Trypsin (1:10 in PBS) was used to detach adherent cells. The number of viable cells was
counted upon 0.1% trypan blue staining with a Roche Cedex XS analyzer (Basel, Switzerland).
2.9. Flow Cytometry
Two 105 CCRF-CEM cells, incubated in 6-well plates for 24 h, were treated with 10 M free and
C60 bound Ber. After 0, 1, 3, and 6 h incubation, cells per sample were analyzed at ex = 488 nm and
em = 530/40 nm with the flow cytometer BD FACSJazz (Franklin Lakes, NJ, USA).
2.10. Fluorescent Microscopy
CCRF-CEM cells were incubated with 10 M Ber and C60-Ber nanocomplexes in a Ber equivalent
concentration. At 0, 1, 3, and 6 h, the cells were examined with a Keyence BZ-9000 BIOREVO
fluorescence microscope (Osaka, Japan), equipped with a green filter (ex = 435 nm, em > 515 nm).
The Keyence BZ-II Viewer acquisition software (Osaka, Japan) was used.
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2.11. Cell Viability Assay
CCRF-CEM cells, cultured in 96-well cell culture plates Sarstedt (Nümbrecht, Germany) for 24 h,
were treated with the 1% FBS medium containing 0–80 M Ber or C60-Ber nanocomplexes in a Ber
equivalent concentration. Cell viability was determined with an MTT reduction assay [69] at 24, 48, and
72 h. Briefly, cells were incubated for 2 h at 37 C in the presence of 0.5 mg/mL MTT. The diformazan
crystals were dissolved in DMSO and determined at 570 nm with a microplate reader Tecan Infinite
M200 Pro (Männedorf, Switzerland).
2.12. Cell Cycle
CCRF-CEM cells (2  105/well, 2 mL) were seeded in 6-well plates, incubated for 24 h, and
subsequently treated with 10 M free and C60-bound Ber. After 12 h incubation, the cells were
harvested, washed with PBS, fixed by adding the cell solution dropwise to ice-cold 70% ethanol/PBS,
mixed, and stored at 20 C overnight. Next, cells were washed with ice-cold PBS and treated with
the working buer containing 100 g/mL RNAse A (in water, preboiled at 95 C for 15 min), 0.1%
triton X-100, and 10 g/mL propidium iodide for 20 min. Consequently, the DNA content of cells was
analyzed with the BD FACSJazz flow cytometer (Franklin Lakes, NJ, USA). A minimum of 2  104
events per sample were acquired and analyzed at ex = 488 nm and em = 692/40 nm with BD FACS
(Franklin Lakes, NJ, USA).
2.13. Caspase 3/7 Activity
CCRF-CEM cells (104/well) were seeded into 96-well plates and incubated for 24 h. Cells were
treated with free C60 and Ber or C60-Ber nanocomplexes in 10 M Ber-equivalent concentration for 0, 1,
3, 6, 12, and 24 h. Activity of caspase 3/7 was determined using the Promega Caspase-Glo® 3/7 Activity
assay kit (Madison, WI, USA) according to the manufacturer’s instruction. Briefly, plates were removed
from the incubator and allowed to equilibrate to room temperature for 30 min. After treatment, an
equal volume of Caspase-Glo 3/7 reagent containing a luminogenic peptide substrate was added
followed by gentle mixing with a plate shaker at 300 rpm for 1 min. The plate was then incubated
for 2 h at room temperature. The luminescence intensity of the products of caspase 3/7 reaction was
measured with the Tecan Infinite M200 Pro microplate reader (Männedorf, Switzerland).
2.14. Statistics
All experiments were carried out with a minimum of four replicates. Data analysis was performed
with the use of the GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, USA). Paired Student’s
t-tests were performed. Dierences values p < 0.01 were considered to be significant. Half-maximal
inhibitory concentration (IC50) value was calculated with specialized software GraphPad Prism
7 (GraphPad Software Inc.). Individual concentration-eect curves were generated by fitting the
logarithm of the compound concentration versus the corresponding normalized cell viability using
nonlinear regression.
3. Results
3.1. Characterization of the C60-Ber Nanocomplex Aqueous Solution
The initial test for possible interaction between C60 and Ber molecules was accomplished by
means of UV–Vis spectroscopy. The Ber molecule exerts an absorption maximum at 344 nm that is
overlapped with C60 absorption peaks, which does not allow for the unambiguous tracking of changes
in the Ber spectrum upon the addition of C60 (Figure 3a). For that reason, we measured a dierential
absorption spectrum as a dierence between the absolute spectrum of the C60-Ber nanocomplex and the
absolute spectrum of pure C60FAS at the same C60 concentration. It can be seen that an increase in C60
concentration resulted in a non-monotonic change in the Ber spectrum with a slight bathochromic shift
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of the absorption maximum (Figure 3b). Very similar spectral indices have been previously noted for the
related aromatic ligands, such as Doxorubicin [57,59], proflavine, and methylene blue [57], confirming
nanocomplex formation with C60 in water. Moreover, the observed changes in the Ber spectrum
appeared to be similar to that reported recently for the C70 and Ber complex [70]. These results evidence
the formation of noncovalent nanocomplexes between C60 and Ber molecules in an aqueous solution.
Figure 3. Absolute absorption spectra of Ber and C60 (a), dierential absorption spectrum of C60-Ber
nanocomplex solution (b), and the dierential absorbance measured at absorption maximum of Ber
molecule and fixed Ber concentration, CD0 = 0.02 mM, as a function of C60 concentration (c).
The Ber absorption change (measured at 344 nm) as a function of C60 concentration is shown
in Figure 3c. An increase in C60 concentration was followed by a systematic increase in the optical
density. This repeated the trendline of the titration curve measured at elevated C60 concentrations for
other ligand molecules [57] and was previously explained as a consequence of ligand adsorption into
large C60 clusters with a further induction of C60 aggregation and a corresponding increase of light
scattering. In the case of Ber, a similar eect could in principle be expected due to the Ber positive
charge, which could attenuate the electrostatic repulsion between C60 molecules inside C60 clusters by
analogy with a well-known eect of induced C60 aggregation in the presence of salts [71].
A preliminary AFM control study included an investigation of layers formed with free Ber and
C60 to ensure the following proper interpretation of the data obtained with the C60-Ber layers.
Ber layers contained molecules grouped in islands on the surface of the substrates. With the
increased concentration of the deposited substance, a growth of the continuous submonolayer film
was detected (Figure 4). AFM estimated the thickness of the Ber islands and submonolayers to be
within a range of 0.35–2.2 nm. The smallest thickness of the submonolayer was found to be in good
agreement with the minimum size of the Ber molecule:  1.47  0.66  0.32 nm [72]. Within one raster
scanning, the thickness of the Ber submonolayer diered by no more than ~0.35 nm, which could be
explained by its dependence on the number of molecular layers, the orientation of molecules in the
submonolayer, the surface concentration of Ber molecules at a particular site, and the condition of their
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deposition. The observed formation of close-packed Ber islands and of submonolayers on the surface
of the substrate indicates the attraction forces in the interaction between Ber molecules.
Figure 4. AFM images of the Ber (concentration 208 M) layer (top) and their Z-profiles along the lines
marked on images (bottom); image size is 20  20 m2.
The investigation of C60 films deposited from an aqueous solution revealed a high degree of
molecule dispersion in the solution. Therefore, the majority of C60 molecules were located chaotically
and separately along the surface (see the dotted objects with a height of ~0.7 nm in Figure 5a), or
in the form of bulk clusters consisting of several molecules (objects with a height of 1.3–2 nm in
Figure 5a). The arrangement of C60 molecules formed because of the electrostatic repulsion between
them. The observed formation of bulk nanoclusters in an aqueous solution is in excellent agreement
with the results of our previous experimental and theoretical studies [39,40].
Figure 5. AFM images: the C60 (concentration: 208 M) layer (a); the C60-Ber (208:208 M) layer (b).
Numbers with arrows show the height of nano-objects. (c) A 3.5  2 m2 fragment (highlighted in
image (b)) with reduced contrast (top) and its Z-profile along the marked line (bottom).
The characterization of the C60–Ber films was challenging due to the close proximity of sizes of
the single C60 and Ber molecules. Therefore, the diameter of C60 (~0.7 nm) is equal to the size of the Ber
molecule along one axis and double the size along the other axis. However, the dierent nature of the
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intermolecular interaction of free C60 and Ber molecules determines the dierent types of adsorption
of these substances, namely the island-like growth of the Ber film and the isolated arrangement of
C60 (nanoclusters), which can be used to identify C60 and Ber molecules in AFM images. As seen
in Figure 5b, the continuous submonolayer was presented in the layer of the nanocomplex system,
typical for Ber films (its thickness is 0.35–0.5 nm). The single objects were detected as well, which we
identified as C60 molecules or their nanoclusters (0.7–2 nm). In the layers of the nanocomplex system,
we observed conglomerates with a height of a few nanometers and a length of up to 1 m (Figure 5b,c),
absent in the layers of free C60 and Ber.
Therefore, it can be assumed that these conglomerates are a mixture of C60 and Ber molecules.
This is indicated by the internal structure of the conglomerate, consisting of nanoaggregates of various
types: A separate height of 1–2.5 nm, against the background of which there are one or several granules
with a height of up to 10 nm (Figure 5c). The origin of conglomerates can be explained by the fact that
the interaction negatively charged C60 nanoclusters [73], and Ber + cations in an aqueous dispersion
are accompanied by their coagulation. Upon deposition on the surface and evaporation of water, a
segregation of the nanocomplex occurs at the initial components with the formation of nanoaggregates
of various types with van der Waals intermolecular interactions. It should be noted that our previous
studies of the structural self-organization of C60 nanocomplexes with anticancer drugs Doxorubicin and
Cisplatin in the physiological buer showed that saline ions interfered with the C60 coagulation [58,59].
Therefore, to reduce the degree of aggregation of the C60-Ber nanocomplex, the development of this
nanosystem in a physiological buer could be promising.
At the same time, DLS measurements show the presence of large particles in the studied samples
(Table 2). Additional aggregation of C60 after the addition of Ber molecules is clearly seen, which
demonstrates the shift of the mean hydrodynamic diameter of light scattering particles to higher
values, i.e., from 82 up to 152 nm. With an increase in Ber molecule content, the size of the particles in
the studied C60–Ber dispersions was increased from 110 to 152 nm. A similar increase in aggregate
size upon the addition of ligand molecules and complex formation has been previously reported for
Doxorubicin [59], ICR-191 [53], and Landomycin A [61].
Table 2. The hydrodynamic diameter of particles, polydispersity index (PDI), and zeta potential
values 1 for the studied samples at room temperature.
Sample Size, nm PDI Zeta Potential, mV
1:2 C60-Ber 152  2, (3 : : : 289) 2 0.44  0.02  19.5  0.5
1:1 C60-Ber 114  2, (3 : : : 207) 2 0.42  0.02  20.6  0.5
2:1 C60-Ber 110  2, (3 : : : 196) 2 0.48  0.02  21.3  0.5
C60FAS 82  2, (3 : : : 126) 2 0.21  0.01  23.9  0.6
1 Results are presented as mean values  SD; 2 The minimum and maximum particle sizes are given in parentheses.
The PDI value, as an indicator of particles’ aggregation in an aqueous medium, was found to be
in the range of 0.42–0.48 for the C60–Ber complexes (Table 2), indicating a high polydispersity of the
studied aqueous dispersions.
The value of the zeta potential was determined to estimate the stability of nanocomplex dispersions.
The zeta potential value for the studied C60-Ber nanocomplexes at room temperature changed from
 19.51 to  21.26 mV (Table 2). This may be explained by Ber cation complexation with a negatively
charged C60 and its nanoclusters in the aqueous dispersion ( 23.9 mV).
The results presented above confirmed the complexation between the Ber molecule and C60. We
then estimated the properties of the 1:1 nanocomplex by analyzing its energy-minimized structure
(Figure 6). The structure reflects a face-to-face orientation of the Ber and C60 molecules’ aromatic
surfaces, with a minimal distance between them of 0.328 nm. This well agrees with the structure of the
1:1 C70–Ber nanocomplex reported by Kyzyma et al. [70].
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Figure 6. The energy-minimized structure of 1:1 C60-Ber nanocomplex.
The structural analysis suggested that -stacking should play a major role in nanocomplex
stabilization in an aqueous solution [74]. The computation of the component’s total binding
energy demonstrated that the net van der Waals (DGvdW   4.1 kcal/mol) and hydrophobic
(DGhyd   9.6 kcal/mol) contributions are the leading factors favoring nanocomplex formation,
whereas the contribution of electrostatic energy is small (DGel  1.3 kcal/mol). A similar pattern
of the component’s binding energy was noted for various ligand molecule binding with C60 [74]
and may therefore be viewed as a “thermodynamic signature” of C60 complexation with small
aromatic molecules.
3.2. Computation of the Equilibrium Constant of Ber Binding with C60 Nanoparticles
In order to estimate the anity of the Ber molecule to C60 nanoparticles in an aqueous dispersion,
we used a standard approach in which the experimental titration curve (Figure 3c) was fitted using the
complexation model, yielding the equilibrium complexation constant as an output search parameter [75].
Previously standard hetero-association models were shown to be not directly applicable for quantifying
C60-ligand complexation by means of UV–Vis spectroscopy because ligand-induced C60 aggregation
leads to pronounced light scattering that strongly influences the titration curve (see the discussion
above). A general up-scaled model of C60-ligand complexation based on UV–Vis titration data has
been recently suggested [60], and it takes into account the eect of ligand-induced C60 aggregation
and the two major processes of ligand binding with C60 nanoparticles, i.e. ligand complexation with
low-dimension C60 clusters with equilibrium constant Kh1 (Process 1) and ligand adsorption into large
C60 clusters with equilibrium constant Kh2 (Process 2). In this model, the absorbance A, as a function of
C60 concentration, C0, is given as
A = "mC0D1 + "h1BKh1C
0
R1C
0
D1 + "h2(CD0  C0D1   BKh1C0R1C0D1) (2)
where "m, "h1, and "h2 are extinction coecients of the ligand in a monomer state, in a complex
with a low dimension and large C60 clusters, respectively ("m equals 22,500 M 1cm 1 for the Ber
molecule [76], CD0 is the ligand concentration, and C0R1 and C
0
D1 (as well as C
0
M0 (see [60] for details))
can be determined from the solution of the system of equations.8>>><>>>: C0 = BC
0
R1 + BKh1C
0
R1C
0
D1 + C
0
M0
1 (1 B)BKFC0R1
1 BKFC0R1
CD0 = C0D1 + BKh1C
0
R1C
0
D1 + C
0
M0
HKh2C0D1
1 Kh2C0D1
(3)
where KF = 56,000 M 1 and B = 0.914.
Unknown parameters in this model are ["h1, "h2, Kh1, Kh2, H], which are determined by a standard
numerical procedure of the minimization of discrepancy between the model (Equation (2)) and
experimental (Figure 3c) titration curves (i.e., the curve fitting procedure).
Pharmaceutics 2019, 11, 586 12 of 23
In the present work, the above-described approach was used in a numerical analysis of Ber
complexation with C60 in an aqueous dispersion. Table 3 contains the magnitudes of the examined
parameters, obtained with the goodness of fit R2 = 0.94, evidencing the appropriateness of the
model used.
Table 3. The calculated parameters of Ber complexation with C60 in an aqueous dispersion.
"h1, M 1cm 1 "h2, M 1cm 1 Kh1, M 1 Kh2, M 1 H
4250 46,100 28,300 4300 22
Analysis of the complexation parameters enables to estimate the specificity of the binding process.
Process 1 is characterized by the high Kh1 magnitude and low molar absorption magnitude "h1, as
compared with the monomer molar absorption (i.e., "m > "h1). This indicates stacking complexation as
a main form of Process 1, correspondent to the calculated structure presented in Figure 6. Process 2 is
characterized by a low Kh2 magnitude and high molar absorption magnitude "h2, as compared with
"m. This evidences the non-specific adsorption of Ber molecules into large C60 clusters as a main form
of Process 2. The resultant parameters are qualitatively similar to that obtained before for the binding
of C60 in water with Doxorubicin and proflavine [60], both of which resemble Ber in terms of structure
and charge state. Thus, the dominating event for binding Ber to C60 in water appears to be Process 1
(-stacking).
3.3. Ber Release from C60-Ber Nanocomplexes
Drug release is an important property of a therapeutic system, constituting a prerequisite to its
biological application. To study the Ber release kinetics, C60-Ber nanocomplexes were incubated in the
complex cell culture medium over 72 h. At 0, 1, 5, 14, 24, 48, and 72 h, the content of unbound free
Ber was assessed with HPLC-ESI-MS/MS. Data obtained from in vitro drug release were plotted as
cumulative amount of drug release versus time (Figure 7).
Figure 7. Berberine release from C60-Ber nanocomplexes during 72 h of incubation in RPMI medium.
Drug release from from 1:2, 1:1, and 2:1 C60-Ber nanocomplexes under common cell culture
conditions, was calculated to reach maximum of 15.68  4.86%, 16.35  5.07% and 18.87  5.29%
correspondingly of the initial concentration at 72 h of incubation (Figure 7). Thus, the content of 1:2, 1:1,
and 2:1 C60-Ber nanocomplexes after incubation in RPMI medium for 72 h remained on the level of 85%.
3.4. Intracellular Accumulation of C60-Ber Nanocomplexes
Strong absorption (Figure 3a) and fluorescence [20] of the Ber molecule in the visible spectral
region enables the tracking of its complexes with the non-invasive, direct fluorescent-based techniques.
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CCRF-CEM cells were incubated in the presence of 10 M Ber or C60-Ber nanocomplexes for 0, 1, 3,
and 6 h and were examined with both fluorescent microscopy and flow cytometry to visualize and
quantify the intracellular Ber uptake (Figure 8). Autofluorescence of the untreated cells was used as a
negative control. The mean fluorescence intensity of each sample, calculated from logarithmic FACS
histograms by the respective value of Ber green fluorescent signal (ex = 488 nm, em = 530/40 nm), is
presented in Table 4.
Figure 8. Intracellular accumulation of the free 10 M Berberine and C60–Ber nanocomplexes in a
Ber-equivalent concentration: flow cytometry (a) and fluorescent microscopy (b) of CCRF-CEM cells
incubated with Ber and C60-Ber nanocomplexes at the molar ratios 1:2, 1:1, and 2:1; scale bar: 20 m.
Table 4. Mean fluorescence intensity (FI) of the intracellular accumulated Ber measured with
flow cytometry.
FI, a.u. 1 h 3 h 6 h
Ber 39  3 45  3 57  5
1:2 C60-Ber 38  2 49  4 80  7 *
1:1 C60-Ber 42  4 59  5 * 79  6 *
2:1 C60-Ber 38  3 57  6 * 81  6 *
* p  0.01 in comparison with the free Ber.
Fluorescent microscopy demonstrated a time-dependent accumulation of 10 M Ber in CCRF-CEM
cells (Figure 8b). According to the literature data, Ber was localized in mitochondria [6] and eectively
bound DNA, suggesting its high nuclear anity [17,21].
Once Ber was complexated with C60, the observed fluorescence intensities were dramatically
enhanced. Microscopy images demonstrated that C60-Ber nanocomplexes were internalized faster
and more eciently in comparison with the free Ber (Figure 8b). The mean fluorescent intensity of
the CCRF-CEM cells (Figure 8a), treated with the 1:2 C60-Ber nanocomplex at 10 M Ber-equivalent
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concentration, was found to be increased by 31% at 6 h. In cells treated with C60-Ber nanocomplexes at
1:1 and 2:1 molar ratios, the fluorescent signal reached the level of 130 and 140% from the control at 3
and 6 h, respectively (Table 4). The data obtained showed that Ber complexation with C60 strongly
promoted its uptake by the leukemic cells.
3.5. Cell Viability
To evaluate the eect of Ber on cancer cell proliferation, CCRF-CEM cells were treated with a free
Ber in increasing concentrations and C60-Ber complexes in Ber-equivalent concentrations for 24, 48,
and 72 h. Cell viability was estimated with an MTT assay (Figure 9).
Figure 9. Viability of CCRF-CEM cells, treated with a free Ber or C60-Ber nanocomplexes in a
Ber-equivalent concentrations for 24 (a), 48 (b), and 72 h (c) (* p  0.01 in comparison with the free
Ber) as well as viability of CCRF-CEM cells, treated with a free C60 in a nanocomplex-equivalent
concentrations for 24, 48, and 72 h (d).
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Free Ber exhibited dose- and time-dependent toxicity towards CCRF-CEM cells in a range of
concentrations from 5 to 50 M (data are not shown). Taking into account the initial aim of anticancer
agent complexation with C60 to potentiate its toxicity and, therefore, decrease ecient dose, we
have chosen a concentration range—from 1.3 to 20 M—for further investigation of the eects of
Ber’s complexation with C60. The pointed concentrations of Ber exhibited mild, if any, cytotoxicity
(Figure 9a–c).
Increasing concentrations of Ber inhibited cell growth in a time- and dose-dependent manner
(Figure 9a–c). The number of viable cells was gradually decreased under the action of Ber in the
concentration range 1.3–20 M. Thus, 10 M Ber decreased CCRF-CEM cell viability to 71  9% and
50  6% from the control at 48 and 72 h, respectively.
All C60-Ber nanocomplexes exhibited stronger antiproliferative potential towards CCRF-CEM
cells in comparison with the free Ber. It should be noted that C60 alone at concentrations equivalent to
those used in nanocomplexes had no significant eect on cell viability (Figure 9d). With the increasing
of C60 concentration in C60-Ber nanocomplexes, a higher toxic potential towards CCRF-CEM cells was
observed, following the order 1:2 < 1:1 < 2:1 (the most toxic). Thus, at 24, 48, and 72 h, the 10 M 1:2
C60-Ber nanocomplex decreased cell viability to 76  8%, 49  8%, and 26  7%; the 10 M 1:1 C60-Ber
nanocomplex to 74  9%, 48  3%, and 25  7%; and 10 M the 2:1 C60-Ber nanocomplex to 60  4%,
34  6%, and 22  7% - all from the control, respectively (Figure 9a–c). The calculated IC50 values for
the free Ber and C60-Ber nanocomplexes, listed in Table 5, evidenced the C60-dependent enhancement
of Ber cytotoxicity. Thus, at 24 h, the IC50 value for Ber after complexation with C60 at the molar ratios
1:2, 1:1, and 2:1 was decreased by 1.3, 1.8, and 2.8 times, respectively; at 48 h, by 2.1, 2.9, and 4.6 times,
respectively; at 72 h, by 3.2, 4.8, and 6.3 times, respectively.
Table 5. Half-maximal inhibitory concentration (IC50) of the free Ber and C60-Ber nanocomplexes
towards CCRF-CEM cells.
IC50, M 24 h 48 h 72 h
Ber 58  5 23  2 19  2
1:2 C60-Ber 44  4 * 11.0  1.2 * 6.0  0.4 *
1:1 C60-Ber 33  3 * 8.0  0.7 * 4.0  0.3 *
2:1 C60-Ber 21  2 * 5.0  0.6 * 3.0  0.2 *
* p  0.01 in comparison with the free Ber.
3.6. Apoptosis Induction
To determine whether C60-Ber nanocomplexes induced apoptosis, we monitored cell cycle
distribution and caspase 3/7 activity in CCRF-CEM cells (Figure 10).
The analysis of flow cytometric cell cycle distribution indicated the accumulation of cells in
the sub G1-phase upon complexation of Ber with C60. Thus, control cells were characterized with
1.94  0.51% cells in the sub G1-phase. C60-treatment of control cells caused no alteration in the cell
cycle distribution at three tested concentrations equivalent to C60-Ber nanocomplexes. CCRF-CEM cells
treated with 10 M Ber for 12 h showed a slight increase in sub G1-cells to 3.48  0.89%. The treatment
of CCRF-CEM cells with 1:2, 1:1, and 2:1 C60-Ber nanocomplexes was followed with an increase in cells
in the sub G1-phase to 10.79  1.21, 10.53  2.01, and 16.28  0.98%, respectively (Figure 10a,b).
Free C60 had no eect on the caspase 3/7 activity at the concentrations used in the nanocomplexes.
In cells treated with the free Ber, a delayed caspase 3/7 activation by 35  8% from the control at 24 h
was observed. However, in cells treated with C60–Ber nanocomplexes, caspase 3/7 activation was
detected starting from 6 h, which reached 170–178  11–14% of the control at 24 h (Figure 10c).
The activation of caspase 3/7 cells indicated the induction of the apoptotic death of CCRF-CEM
cells treated with C60-Ber nanocomplexes.
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Figure 10. Apoptosis induction: cell cycle analysis in CCRF-CEM cells, incubated for 24 h after treatment
with and without free C60, Ber or C60-Ber nanocomplexes at 10 M Ber equivalent concentration
presented with flow cytometry histograms (a) and a bar graph (b), which depicts the mean percentage
of each cell cycle phase; caspase 3/7 activity in CCRF-CEM cells (c), incubated for 24 h after treatment
with either free C60, Ber, or C60-Ber nanocomplexes at 10 M Ber equivalent concentration (caspase 3/7
activity of untreated cells is set to 100%).
4. Discussion
The constantly increasing interest in novel nanotechnology platforms for biomedical applications
stimulated the investigation and application of carbon nanomaterials including C60 as a representative
of the fullerenes family. The supramolecular self-assembly based on – stacking interactions between
unsaturated (poly)cyclic molecules is commonly used for the fast, easy, and cost-eective coupling
of cargo molecules with carbon nanoparticles [77,78] and for improving drug stability and loading
capacity [79].
In previous studies, we exploited the ability of the polyaromatic C60 surface to absorb
dierent therapeutics and created the C60 drug-carrying nanocomplexes. In a pioneering attempt,
Evstigneev et al. [57] showed a simple and fast method of noncovalent C60 complexation with
Doxorubicin in water and later in a physiological solution [59]. The strategy was applied for
C60 complexation with other chemotherapeutic drugs including Cisplatin and Landomycin A.
Molecular modeling, spectroscopy, atomic-force microscopy, mass spectrometry, dynamic light, and
small-angle X-ray/neutron scattering evidenced nanocomplex formation [54,56,59,60,80]. The proposed
nanosystems were shown to have a higher toxicity compared with the free drugs in vitro and in vivo [54].
In the current study, nanocomplexes of C60 and the herbal alkaloid Ber at the 1:2, 1:1, and 2:1
molar ratios were prepared, characterized, and tested on human leukemic cells in vitro.
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UV–Vis spectroscopy revealed that an increase in C60 concentration was followed by a
non-monotonic change in the Ber spectrum with a slight bathochromic shift in its absorption
maximum, which was induced by the ligand adsorption into large C60 clusters. C60-Ber nanocomplexes
were prepared in the 1:2, 1:1, and 2:1 molar ratios. The increase in Ber concentrations in C60-Ber
nanocomplexes was followed by the gradual increase in the particle size from 110 to 152 nm and in the
zeta potential value from  21.26 to  19.51 mV, which was linked to the Ber-induced C60 aggregation
and complexation of Ber cations with negatively charged C60. Finally, an AFM study indicated the
internal structure of the 1:1 C60-Ber aqueous dispersion, consisting in particular of small nanoaggregates
with a height of 1–2.5 nm.
The size of the proposed nanocomplexes could be classified as advantageous in that they are
eciently taken up by cancer cells, since the literature evaluation and discussion so far suggest an
optimum size around 100–200 nm. This range is limited by the leaky tumor vessels, with the higher
extravasation of macromolecules in a 10–500 nm size from one side [81–84], and the lymphatic system
activation and the quick removal from a circulation of 200 nm nanoparticles from another side [85].
Finally, the computer simulation revealed that -stacking was the dominating event in Ber and
C60 binding in aqueous dispersions and allowed for the proposal of the energy-minimized structure of
the 1:1 C60–Ber nanocomplex with a 1.05 nm minimum distance from C60 to the Ber nitrogen atom and
1.42 nm maximum distance from C60 to the Ber hydrogen atom. The obtained analytical data and the
analysis of the Ber and C60 complexation parameters indicated the nanocomplex formation and their
stability for in vitro studies.
With the use of the fluorescent microscopy and the flow cytometry, we confirmed the intracellular
accumulation of the alkoloid in human leukemic CCRF-CEM cells treated with the free Ber or C60-Ber
nanocomplexes. C60-Ber nanocomplexes appeared to be internalized by CCRF-CEM cells faster
and more intensively then the free Ber. The intracellular Ber accumulation is determined by two
independent processes—Ber entry into the cell and its eux from the cell. Free Ber permeates the
cells through the passive diusion [86], while C60 enters the cell not only due to passive diusion [87],
but also by endocytosis/pinocytosis [88,89] and phagocytosis [90]. Therefore, C60 could function as a
transporter of the small aromatic molecules [53], facilitating its intracellular uptake. From the other
hand, Ber was reported to be a substrate of P-glycoprotein [91], responsible for the fast pumping of
drugs from the cancer cell. However, C60 is not recognized by P-glycoprotein [92] and is even shown to
bind P-glycoproteins [55], inhibiting its activity. Taken together, these data indicate that the enhanced
cytotoxic eect of C60-Ber nanocomplexes can be linked to the increased alkoloid’s accumulation in
leukemic cells.
Cell viability assay revealed a time- and concentration-dependent toxic eect of Ber towards
CCRF-CEM cells. IC50 values were estimated to be 58  5, 23  2, and 19  2 M at 24, 48, and 72 h,
respectively. The IC50 of Ber in 1:2, 1:1, and 2:1 C60–Ber nanocomplexes was decreased at 72 h by 3.2,
4.8, and 6.3 times, respectively, following the order 1:2 < 1:1 < 2:1 (the most toxic). The activation of
caspase 3/7 and altered cell cycle distribution in CCRF-CEM cells indicated the apoptotic cell death
induction under C60-Ber nanocomplexes action.
The enhanced toxic eciency of Ber against leukemic cells upon its complexation with C60 as
compared with the free drug is determined by C60’s ability to promote drug accumulation inside
cancer cells and potentiate its toxic activity. Complexation with C60 allowed us to enhance Ber
toxicity against leukemic cells more appreciably as compared with C60 complexation with traditional
anticancer therapeutic Doxorubicin, which was followed by a less than 3.5-fold decrease of IC50 at
the same treatment duration [56]. This can be linked to the higher concentration of the safe Ber in the
C60-containing nanocomplex (M of Ber against nM of Doxorubicin). The obtained results encourage
the strategy of C60 usage for natural anticancer medicine delivery.
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5. Conclusions
In the presented study, the fast and easy noncovalent complexation strategy of aromatic cargo
with C60 fullerene was used to deliver the herbal alkaloid Ber into leukemic cells.
The UV–Vis spectroscopy, DLS, and AFM techniques may confirm the complexation of C60 with
the Ber molecule in an aqueous dispersion, and computer simulation allowed for the proposal of the
energy-stable structure of 1:1 C60-Ber nanocomplex with a size of up to ~1.4 nm.
Fluorescence-based techniques evidenced that C60–Ber nanocomplexes were more quickly and
more intensely internalized by leukemic CCRF-CEM cells and exhibited a stronger antiproliferative
potential as compared with free Ber. The IC50 value for Ber in C60-Ber nanocomplexes at 1:2, 1:1,
and 2:1 molar ratios was found to be decreased by 3.2, 4.8, and 6.3 times, respectively, as compared
with the IC50 value for the free Ber. The activation of caspase 3/7 and increase of the sub-G1 cell
cycle phase in CCRF-CEM cells indicated the apoptotic cell death induction under treatment with
C60-Ber nanocomplexes.
The results of this study suggest the formation of a noncovalent nanocomplex between herbal
alkaloid Ber and C60 fullerene. The complexation of Ber with C60, as a nanocarrier, enhanced its uptake
by leukemic cells with toxic eects. Our results provide a proof of concept of the strategy of using C60
for natural medicine nanodelivery.
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